Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

UnitedHealth Group is under investigation by the Justice Department **over its Medicare billing prac ...

Hims & Hers Health (HIMS) shares nosedive on news from the US Food and Drug Administration (FDA) that the shortage in ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Key TakeawaysHims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and ...

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.